Quantcast
Channel: New Drug Approvals
Viewing all articles
Browse latest Browse all 2871

Fandofloxacin In phase 2 by Dong Wha Pharmaceutical Co Ltd

$
0
0

DW-116; fandofloxacin

164150-99-6 FREE BASE ,

164151-00-2., 164150-85-0
6-fluoro-1-(5-fluoropyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid

6-Fluoro-1-(5-fluoropyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

Dong Wha Pharmaceutical Co Ltd

Molecular Formula: C20H18F2N4O3

Molecular Weight: 400.378726

synthesis………….http://www.drugfuture.com/synth/syndata.aspx?ID=226498

http://www.google.com.mx/patents/WO1995005373A1

 

synthesis 1

 

Condensation of ethyl 2,4,5-trifluorobenzoylacetate (I) with triethyl orthoformate in refluxing Ac2O produced the benzoyl ethoxyacrylate (II), which was further condensed with 2-amino-5-fluoropyridine (III) to afford enamine (IV). Cyclization of (IV) in the presence of K2CO3 gave rise to the quinolone (V). The 7-fluoride group of (V) was then displaced by N-methylpiperazine (VI) in cold pyridine to furnish the piperazinyl quinolone (VII). Finally, ester hydrolysis in (VII) under acidic conditions yielded the target compound. In a closely related procedure, ester (V) was hydrolyzed to acid (VIII) using HCl. Subsequent displacement of the 7-fluoride of (VIII) with N-methylpiperazine (VI) provided the desired piperazinyl quinolone.

 

synthesis 2

Condensation of ethyl 2,4,5-trifluorobenzoylacetate (I) with triethyl orthoformate in refluxing Ac2O produced the benzoyl ethoxyacrylate (II), which was further condensed with 2-amino-5-fluoropyridine (III) to afford enamine (IV). Cyclization of (IV) in the presence of K2CO3 gave rise to the quinolone (V). The 7-fluoride group of (V) was then displaced by N-methylpiperazine (VI) in cold pyridine to furnish the piperazinyl quinolone (VII). Finally, ester hydrolysis in (VII) under acidic conditions yielded the target compound. In a closely related procedure, ester (V) was hydrolyzed to acid (VIII) using HCl. Subsequent displacement of the 7-fluoride of (VIII) with N-methylpiperazine (VI) provided the desired piperazinyl quinolone.

Synthesis, pharmacokinetics, and biological activity of a series of new pyridonecarboxylic acid antibacterial agents bearing a 5-fluoro-2-pyridyl group or a 3-fluoro-4-pyridyl group at N-1
J Heterocycl Chem 1997, 34(3): 1021

6-31-2011
PHARMACEUTICAL COMPOSITION
8-24-2007
PHARMACEUTICAL COMPOSITION
6-29-2007
PHARMACEUTICAL COMPOSITION
10-28-2005
Identification and use of effectors and allosteric molecules for the alteration of gene expression
7-15-2005
Pharmaceutical composition
2-6-2004
Medicinal composition
4-20-2000
NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVES
3-6-1996
Quinolone carboxylic acid derivatives
2-24-1995
NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVES

 


Filed under: Phase2 drugs Tagged: fandofloxacin, phase 2

Viewing all articles
Browse latest Browse all 2871

Trending Articles